title: [Development of antibody drugs targeting against HER2 for cancer therapy].
abstract: Human epidermal growth factor receptor 2 (HER2) belongs to the transmembrane glycoprotein receptor family. Overexpression of HER2 could directly lead to tumorigenesis and metastasis. This phenomenon could be observed in the breast cancer, ovarian cancer, gastric cancer, lung cancer and prostate cancer. Compared with the conventional chemotherapy, the targeted treatment of antibody is more specific and has lower side effects. This review describes the current status of monotherapy and combination therapies of anti-HER2 antibodies, trastuzumab and pertuzumab, with chemotherapeutic drugs. The development trends of new formats of anti-HER2 antibody drugs such as bispecific antibody, immunotoxin are also discussed.
authors.affiliation: Department of Biochemistry, School of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Qin
authors.initials: Q
authors.lastname: Tang
authors.forename: Qian
authors.initials: Q
authors.lastname: Ding
authors.forename: Li
authors.initials: L
authors.lastname: Lin
authors.forename: Zhen-zhen
authors.initials: ZZ
authors.lastname: Zhang
authors.forename: Zheng
authors.initials: Z
authors.lastname: Dai
authors.forename: Jin-biao
authors.initials: JB
authors.lastname: Zhan
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D000922:Immunotoxins / Q000627:therapeutic use; D009369:Neoplasms / Q000378:metabolism / Q000628:therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000922:Immunotoxins; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C485206:pertuzumab